| Number of cases (%) |
---|---|
Gender | |
Male | 89 (56.0%) |
Female | 70 (44.0%) |
Age (years) | |
≥47 | 81 (50.9%) |
< 47 | 78 (49.1%) |
Clinical Stage | |
I | 16 (10.1%) |
II | 58 (36.5%) |
III | 39 (24.5%) |
IV | 46 (28.9%) |
T classification | |
T1 | 17 (10.7%) |
T2 | 72 (45.3%) |
T3 | 37 (23.3%) |
T4 | 33 (20.8%) |
N classification | |
N0 | 118 (74.2%) |
N1 | 21 (13.2%) |
N2 | 20 (12.6%) |
N3 | 0 (0.0%) |
M classification | |
No | 113 (71.1%) |
Yes | 46 (28.9%) |
Pathologic Differentiation | |
Poor | 101 (63.5%) |
Moderate | 4 (2.5%) |
Well | 54 (34.0%) |
Histological Types | |
MEC | 37 (23.3%) |
ACC | 23 (14.5%) |
AcCC | 18 (11.3%) |
SDC | 18 (11.3%) |
Other histological types | 63 (39.6%) |
Vital status (at follow-up) | |
Alive | 107 (67.3%) |
Death (All Salivary Gland cancer-related) | 52 (32.7%) |
Adjuvant Therapy | |
Yes | 50 (31.5%) |
No | 109 (68.6%) |